<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-13MNX0RV/f4ae4580-6f8c-4e79-ac2b-ee3fef798cd8/HTML"><dcterms:extent>31 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-13MNX0RV/78c94b93-c1df-48bd-b4f8-2bff3be09e10/PDF"><dcterms:extent>477 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-13MNX0RV/1a7a23d1-fe48-42a0-9794-bad2b239ce75/TEXT"><dcterms:extent>28 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1929-2026"><edm:begin xml:lang="en">1929</edm:begin><edm:end xml:lang="en">2026</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-13MNX0RV"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp" /><dcterms:issued>2010</dcterms:issued><dc:creator>Stirn-Kranjc, Branka</dc:creator><dc:format xml:lang="sl">7 strani</dc:format><dc:format xml:lang="sl">letnik:79</dc:format><dc:format xml:lang="sl">str. I-46-I-52</dc:format><dc:format xml:lang="sl">številka:suplement</dc:format><dc:identifier>ISSN:1318-0347</dc:identifier><dc:identifier>COBISSID:27812569</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-13MNX0RV</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko zdravniško društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Zdravniški vestnik</dcterms:isPartOf><dc:subject xml:lang="sl">Blefarospazem</dc:subject><dc:subject xml:lang="en">Blepharospasm</dc:subject><dc:subject xml:lang="sl">botulin A</dc:subject><dc:subject xml:lang="en">Botulinum Toxin Type A</dc:subject><dc:subject xml:lang="sl">Botulinum, toksin tip A</dc:subject><dc:subject xml:lang="en">Drug Therapy</dc:subject><dc:subject xml:lang="en">Facial Paralysis</dc:subject><dc:subject xml:lang="en">Facialna paraliza</dc:subject><dc:subject xml:lang="sl">oftalmologija</dc:subject><dc:subject xml:lang="sl">Oftalmoplegija</dc:subject><dc:subject xml:lang="en">Ophthalmoplegia</dc:subject><dc:subject xml:lang="en">Strabismus</dc:subject><dc:subject xml:lang="sl">Strabizem</dc:subject><dc:subject xml:lang="en">therapy</dc:subject><dc:subject xml:lang="en">Treatment Outcome</dc:subject><dc:subject xml:lang="sl">zdravljenje</dc:subject><dc:subject xml:lang="sl">Zdravljenje, izid</dc:subject><dcterms:temporal rdf:resource="1929-2026" /><dc:title xml:lang="sl">Toksin botulin A v oftalmologiji| 20 let uporabe na Očesni kliniki Ljubljana| after 20 years of its use at the University eye hospital Ljubljana| Botulinum A toxin in ophtalmology|</dc:title><dc:description xml:lang="sl">Background: Botulinum toxin A is a pre-synaptic neurotoxin, clinically effective not only in focal dystonias, but also in oculomotor problems and in oculoplastic surgery. Patients and methods: Botulinum A has been used at the Eye Hospital Ljubljana since 1988 to treat essential blepharospasm, hemifacialspasm, some paralytic and concomitant strabismus forms in oculoplastic procedures. Standard toxin doses and injection techniques are applied with care to possible immunological mechanisms. Results: Botulinum A was used in 882 patients with blepharospasm, in 77 with hemifacial spasm, in 27 patients with oculomotor dysfunction (strabismus, thyroid ophthalmopathy). Its use in oculoplastics (entropion, therapeutic ptosis, cosmetics) was considered only in individual patients. Our patients were adults, 28-94 year old (avarage age 72 years), mostly women, with 1-23 toxin applications. Our success rate was 97 %, constant, avarage effect duration was 16.5 weeks, even longer effect of patientćs wellness. Complication rate was below 10 %, with mild, temporary side effects like pain at the injection site, ecchymosis, ptosis with or without diplopia, dry eye sensation. Conclusions: Therapeutic use of botulinum toxin A is expected to grow, its application is simple and safe. To keep it this way for the gratifying results, the treating physician is well advised to learn the toxin properties, the anatomy and function of theextraocular muscles, and facial structures, to develop the skills of appropriate toxin adminstration and patient selection</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-13MNX0RV"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-13MNX0RV" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-13MNX0RV/78c94b93-c1df-48bd-b4f8-2bff3be09e10/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by-nc/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko zdravniško društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-13MNX0RV/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-13MNX0RV" /></ore:Aggregation></rdf:RDF>